NCT01916720View on ClinicalTrials.gov

Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid Endarterectomy

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

July 31, 2003

Study Completion Date

July 31, 2003

Conditions
Atherosclerosis
Interventions
DRUG

SB-480848 40 mg

Study Drug

DRUG

SB-480848 80 mg

Study Drug

DRUG

Placebo

Study Drug

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01916720 - Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid Endarterectomy | Biotech Hunter | Biotech Hunter